The identification of 14-3-3 [sigma] as a contributor to cisplatin resistance in esophageal squamous cell carcinoma
Esophageal squamous cell carcinoma (ESCC) is the predominant type of esophageal cancer in Asia. Cisplatin is commonly used as an agent for treating ESCC patients undergoing chemotherapy. However establishment of resistance over the course of treatment diminishes the clinical usefulness and is one re...
Main Authors: | Lai, King-yin, 賴景然 |
---|---|
Language: | English |
Published: |
The University of Hong Kong (Pokfulam, Hong Kong)
2015
|
Subjects: | |
Online Access: | http://hdl.handle.net/10722/208627 |
Similar Items
-
Survival rate of patients with esophageal squamous cell carcinoma
by: A Basi, et al.
Published: (2017-05-01) -
Clinical Efficacy of Anlotinib Combined with Paclitaxel and Cisplatin as First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma
by: YANG Xiaoli, et al.
Published: (2021-07-01) -
Screening and Identifying Cisplatin-Related Gene Mutations in Lung Squamous Cell Carcinoma
by: Li X, et al.
Published: (2020-12-01) -
PER2 Circadian Oscillation Sensitizes Esophageal Cancer Cells to Chemotherapy
by: Juan Alfonso Redondo, et al.
Published: (2021-03-01) -
Long‐term results of a randomized controlled trial comparing neoadjuvant Adriamycin, cisplatin, and 5‐fluorouracil vs docetaxel, cisplatin, and 5‐fluorouracil followed by surgery for esophageal cancer (OGSG1003)
by: Keijiro Sugimura, et al.
Published: (2021-01-01)